Bone: Osteocyte RANKL in bone homeostasis: a paradigm shift?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

1. RANKL and RANK in extracellular vesicles: surprising new players in bone remodeling.Extracellular vesicles and circulating nucleic acids · 2021
   Article
2. Actin and Actin-Associated Proteins in Extracellular Vesicles Shed by Osteoclasts.International journal of molecular sciences · 2019
   Review
3. The osteocyte as a therapeutic target in the treatment of osteoporosis.Therapeutic advances in musculoskeletal disease · 2014
   Review
4. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice.PLoS biology · 2012
   Article

Corrections and comments

• Comment on
  Matrix-embedded cells control osteoclast formation.2011
• Comment on
  Evidence for osteocyte regulation of bone homeostasis through RANKL expression.2011

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.